We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of zinc acetate hydrate and polaprezinc for zinc deficiency in patients on maintenance hemodialysis: A single‐center, open‐label, prospective randomized study.
- Authors
Okamoto, Teppei; Hatakeyama, Shingo; Konishi, Sakae; Okita, Kazutaka; Tanaka, Yoshimi; Imanishi, Kengo; Takashima, Tooru; Saitoh, Fumitada; Suzuki, Tadashi; Ohyama, Chikara
- Abstract
The efficacy and safety of zinc acetate hydrate (ZAH) for zinc supplementation in patients on maintenance hemodialysis (MHD) remains unknown. In this prospective, single‐center, open‐label, parallel‐group trial for MHD patients with serum zinc level <70 μg/dL, we compared ZAH (zinc; 50 mg/day) and polaprezinc (PPZ; zinc; 34 mg/day) beyond 6‐month administration in a 1:1 randomization manner. The ZAH and PPZ groups had 44 and 47 patients, respectively. At 3 months, the change rate of serum zinc levels in the ZAH group was significantly higher than that in the PPZ group. Three months after the study, serum copper levels significantly decreased in the ZAH group, but not in the PPZ group. No significant differences were noted in anemia management in either group. ZAH was superior to PPZ in increasing serum zinc levels. Clinicians should note the stronger decline in serum copper levels when using ZAH for MHD patients.
- Subjects
ZINC acetate; ZINC; HEMODIALYSIS patients; LONGITUDINAL method; HYDRATES
- Publication
Therapeutic Apheresis & Dialysis, 2020, Vol 24, Issue 5, p568
- ISSN
1744-9979
- Publication type
Article
- DOI
10.1111/1744-9987.13461